Insider Buying: FocalTherics (NASDAQ:FOCL) CEO Buys $99,750.00 in Stock

FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes bought 21,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $99,750.00. Following the purchase, the chief executive officer owned 626,649 shares in the company, valued at $2,976,582.75. This trade represents a 3.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

FocalTherics Stock Up 2.3%

Shares of FOCL opened at $4.36 on Thursday. The firm’s 50-day moving average is $5.37. FocalTherics has a twelve month low of $1.30 and a twelve month high of $6.40. The company has a market capitalization of $163.41 million, a PE ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.60.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. Analysts expect that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on FOCL. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday. Mizuho set a $15.00 target price on shares of FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.75.

Hedge Funds Weigh In On FocalTherics

Institutional investors and hedge funds have recently made changes to their positions in the business. Leonteq Securities AG bought a new stake in FocalTherics in the fourth quarter worth $313,000. Kovack Advisors Inc. bought a new position in shares of FocalTherics during the fourth quarter valued at about $53,000. Rock Springs Capital Management LP grew its stake in shares of FocalTherics by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after buying an additional 16,500 shares during the last quarter. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter worth about $2,623,000. Finally, SmartHarvest Portfolios LLC purchased a new position in shares of FocalTherics in the first quarter worth about $38,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.